Ocular rosacea

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights

Retrieved on: 
Monday, September 11, 2023
Infection, Pharma, Chalazion, Eyelash, Ocular rosacea, Signs and symptoms, Research, Inflammation, IgG4-related ophthalmic disease, Causes, Eyelid, DLI, Biological soil crust, Immune system, Growth, MITES, Ageing, Patient, Itch, Diagnosis, Stye, Meibomian gland dysfunction, Gland, FDA, R, Red, NIH, Skin, NME, Disease, Cosmetics, Agriculture, Medical device, Pharmaceutical industry, Demodex

Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.

Key Points: 
  • Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions.
  • Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.
  • According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis .

Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis

Retrieved on: 
Wednesday, September 28, 2022
People, Janus, Adult, American Academy, EASI, Inflammation, Ocular rosacea, Safety, Awareness, Immunology, National Institute of Infectious Diseases, AD, Atopic dermatitis, Itchy, Conjunctivitis, Infection, Patient, Clinical trial, Immune-mediated inflammatory diseases, Forearm, Bleeding, Emotional well-being, Quality of life, American Academy of Dermatology, Eczema Area and Severity Index, JAK, Anxiety, Sleep, Briony Behets, Association, Overalls, PALO, BID, Skin, Asthma, HIV disease progression rates, Immune system, Depression, National Institute, Pharmaceutical industry, Vaccine, Silk, IRAK4, Dermatitis, Dermatology

The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites across the United States.

Key Points: 
  • The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites across the United States.
  • The Phase 2a study follows the successful completion of a Phase 1 healthy volunteer study which evaluated 18 adult patients with EVO101 0.1% topical cream, applied twice daily to the ventral aspect of one forearm for seven days.
  • In the Phase 2a study, AD patients will apply EVO101 cream twice daily for eight weeks.
  • "From inception, we have remained focused on rapidly progressing multiple candidates into proof-of-concept clinical studies," said Luis Pea, President and Chief Executive Officer of Evommune.

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Retrieved on: 
Monday, September 20, 2021
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Irritation, Rosacea, Duane syndrome, Exocrine gland, Glaucoma surgery, Security (finance), IgG4-related ophthalmic disease, Hidradenitis suppurativa, Inflammation, Acetylcholinesterase, Ocular rosacea, Retina, U.S. Securities and Exchange Commission, Patient, GKOS, Cross-link, Corporation, Blepharitis, MIGS, Ophthalmology, Atopic dermatitis, Technology, Research, Parasitism, Dermatology, Safety, Glaucoma, NYSE, Cornea, Skin, Acne, Pharmaceutical industry, Attillaps, Glaukos, ATTILLAPS, GLAUKOS

Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease.

Key Points: 
  • Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease.
  • Under the agreement, Glaukos has the exclusive global right to research, develop, manufacture and commercialize products using certain acetylcholinesterase (AChE) inhibitors for the treatment of ophthalmic diseases caused by Demodex mites.
  • Attillaps lead compounds have demonstrated promising in-vitro results in preclinical settings.
  • This licensing agreement adds a promising therapeutic class that expands the focus of our emerging Corneal Health franchise into new and globally underserved disease indications, said Thomas Burns, Glaukos president and chief executive officer.

Rosacea Market - Growth, Trends, and Forecast (2019 - 2024)

Retrieved on: 
Monday, July 15, 2019
Organ systems, Acneiform eruptions, Medicine, RTT, Rosacea, Disease, Ocular rosacea, Small intestinal bacterial overgrowth

Although there is no cure for rosacea, treatments can control and reduce the signs and symptoms associated with the disease.

Key Points: 
  • Although there is no cure for rosacea, treatments can control and reduce the signs and symptoms associated with the disease.
  • The prevalence of rosacea was highest when self-reported, with a rate of 9.71 %( 737,960,000), while the rate of dermatologist-diagnosed rosacea was 5.53 % (420,280,000).
  • However, the presence of generic drugs to curb the related symptoms hinders the growth of the rosacea market.
  • So, the high usage of antibiotics for the treatment of rosacea is the main factor for the growth of the market.